AMR Benchmark homepage

Feature - 23 Jan 2018

The superbugs can be stopped - if we put good ideas into action

The 2018 AMR Benchmark compares for the first time how a cross-section of the pharmaceutical industry is responding to the threat from drug-resistant infections. Executive Director, Jayasree K. Iyer, gives her take on the new research.

The AMR Benchmark: First report on pharma's response to AMR

The 2018 Antimicrobial Resistance Benchmark compares how pharmaceutical companies are bringing AMR under control. It covers R&D, responsible manufacturing, appropriate access and stewardship.

What leaders say

All endorsements

“To control drug resistance, pharma companies first need to stay in the game. The AMR Benchmark looks at the biggest players still making antibacterials and antifungals and addresses whether they are resilient enough for the tough market conditions.”

Jayasree K. Iyer

Executive Director Access to Medicine Foundation

View our media coverage

Learn more

View our detailed overview of each company’s performance